GlassScriptPhysician profile
Matthew S Katz
NPI 1548655566
$8,518.67
in general payments reported to CMS, 2019-2025
26 companies · $905 in 2025
The $905 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.32 · 2022: $6,036 · 2023: $795 · 2024: $708 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,720.91 | 2022-2025 | Cardiomems, Coroflow, Nc Trek Neo |
| Medtronic, INC. | $2,983.45 | 2022-2025 | Ffrangio, Onyx Frontier, Symplicity G3 |
| Shockwave Medical, INC | $722.14 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $202.51 | 2024-2025 | Impella |
| Endologix LLC | $150.00 | 2025 | Torus Stent Graft System, Endocross Device |
| Penumbra, INC. | $129.26 | 2023 | Indigo System |
| Amgen INC. | $95.00 | 2023-2025 | Repatha |
| Coloplast Corp | $74.32 | 2019 | |
| Cardiva Medical, INC. | $60.06 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire, Other |
| Terumo Medical Corporation | $37.82 | 2022 | |
| Baxter Healthcare | $37.19 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $32.51 | 2024 | Eliquis |
| Endotronix, INC. | $31.08 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Boston Scientific Corporation | $24.66 | 2025 | Filterwire Ez |
| Atricure, INC. | $24.44 | 2025 | Atriclip Laa Exclusion System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $24.36 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $22.95 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.56 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.89 | 2022 | |
| Pfizer INC. | $17.00 | 2024 | |
| Impulse Dynamics (USA) INC. | $16.88 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $16.25 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $16.15 | 2024 | Nexletol |
| Azurity Pharmaceuticals, INC. | $15.65 | 2024 | Edarbyclor |
| Merck Sharp & Dohme LLC | $14.88 | 2023 | Verquvo |
| Cvrx, INC. | $8.75 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.